CD8A and neoplasm: In animal studies, while each individual inhibition does not significantly hamper the growth of CT26 tumors, the inhibition of TIGIT and PD-1/PD-L1 enhances the activity of anti-tumor CD8+ T cells and leads to a complete reduction in tumor size [63].